Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 3/20 | 0.58 |
| ▸ | ERCC4 | Q92889 | 3/20 | 0.58 |
| ▸ | ARG1 | P05089 | 1/20 | 0.49 |
| ▸ | SSTR3 | P32745 | 9/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108594 | 1.00 | ERCC1 (0.58) | ERCC1ERCC4ARG1SSTR3CA1 | |
| SCHEMBL8231045 | 1.00 | ERCC1 (0.58) | ERCC1ERCC4ARG1SSTR3CA1 | |
| SCHEMBL8346672 | 0.84 | HRH3 (0.61) | ERCC1ERCC4ARG1 | |
| SCHEMBL13868598 | 0.81 | ERCC1 (0.53) | ERCC1ERCC4ARG1CA1CA2 | |
| SCHEMBL109025 | 0.81 | ERCC1 (0.53) | ERCC1ERCC4ARG1CA1CA2 | |
| SCHEMBL8318520 | 0.81 | KDM4E (0.53) | SSTR3ALOX15 | |
| SCHEMBL8235938 | 0.75 | KDM1A (0.59) | SSTR3 | |
| SCHEMBL24820100 | 0.72 | LTA4H (0.44) | ERCC1ERCC4SSTR3 | |
| SCHEMBL107957 | 0.72 | ARG1 (0.63) | ERCC1ERCC4ARG1CA1CA2 | |
| SCHEMBL3899511 | 0.72 | KDM1A (0.56) | SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227643-B2 | Sirtuin 1 and the treatment of neurodegenerative diseases | PROTEOTECH, INC. (US) | 2012-07-24 | — | — | US | claimed |
| US-20120058998-A1 | Compounds, Compositions and Methods for the Treatment of Inflammatory Diseases | PROTAMED, INC. | 2012-03-08 | — | — | US | claimed |
| US-20110144124-A1 | Compounds and Compositions for Use as Modulators of Tau Aggregation and Alleviation of Tauopathies | PROTAMED, INC. | 2011-06-16 | — | — | US | claimed |
| US-20110015272-A1 | Sirtuin 1 and the Treatment of Neurodegenerative Diseases | PROTEOTECH INC. | 2011-01-20 | — | — | US | claimed |
| US-7714170-B2 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | PROTEOTECH, INC. (US) | 2010-05-11 | — | — | US | claimed |
| US-7601876-B2 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | PROTEOTECH, INC. (US) | 2009-10-13 | — | — | US | claimed |
| US-20090143374-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | PROTAMED, INC. | 2009-06-04 | — | — | US | claimed |
| WO-2008154083-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | PROTEO TECH INC. (US) | 2008-12-18 | — | — | WO | claimed |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | PROTEOTECH, INC. | 2007-11-29 | — | — | US | claimed |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | PROTAMED, INC. | 2007-09-27 | — | — | US | claimed |
| US-20060199838-A1 | Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | PROTAMED, INC. | 2006-09-07 | — | — | US | claimed |
| US-20040127555-A1 | bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis | PROTAMED, INC. | 2004-07-01 | — | — | US | claimed |
| US-20170008838-A1 | COMPOUNDS AND COMPOSITIONS FOR USE AS MODULATORS OF TAU AGGREGATION AND ALLEVIATION OF TAUOPATHIES | PROTAMED INC (US) | 2017-01-12 | — | — | US | disclosed |
| US-9469605-B2 | Compounds and compositions for use a modulators of tau aggregation and alleviation of tauopathies | PROTAMED, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9051253-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's | PROTEOTECH INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051253-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's | PROTEOTECH INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20060199838-A1 | Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | PROTAMED, INC. | 2006-09-07 | — | — | US | disclosed |
| EP-1511710-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER S DISEASE, TYPE 2 DIABETES, AND PARKINSON S DISEASE | Proteotech, Inc. (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040127555-A1 | bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis | PROTAMED, INC. | 2004-07-01 | — | — | US | disclosed |
| WO-2003101927-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE | PROTEOTECH, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127555-A1 | bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis | IAPP, SNCA, IDE | ERCC1 4179/4885ERCC4 3894/4885ARG1 4857/4885 |
| US-20110144124-A1 | Compounds and Compositions for Use as Modulators of Tau Aggregation and Alleviation of Tauopathies | PSEN2, PSEN1, MAPT | ERCC1 3816/4885ERCC4 3592/4885ARG1 1956/4885 |
| US-20060199838-A1 | Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | IAPP, SNCA, BACE2 | ERCC1 4570/4885ERCC4 4543/4885ARG1 3221/4885 |
| US-20120058998-A1 | Compounds, Compositions and Methods for the Treatment of Inflammatory Diseases | NR1H2, NR1H3, MSR1 | ERCC1 3561/4885ERCC4 4660/4885ARG1 830/4885 |
| US-20170008838-A1 | COMPOUNDS AND COMPOSITIONS FOR USE AS MODULATORS OF TAU AGGREGATION AND ALLEVIATION OF TAUOPATHIES | PSEN2, PSEN1, MAPT | ERCC1 3816/4885ERCC4 3592/4885ARG1 1956/4885 |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | IAPP, SNCA, APP | ERCC1 4216/4885ERCC4 4094/4885ARG1 4385/4885 |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | SNCA, PARK7, COMT | ERCC1 2635/4885ERCC4 2782/4885ARG1 4732/4885 |
| US-20090143374-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | APP, BACE1, BACE2 | ERCC1 4174/4885ERCC4 4361/4885ARG1 3472/4885 |
| US-20110015272-A1 | Sirtuin 1 and the Treatment of Neurodegenerative Diseases | SIRT1, SIRT3, SIRT2 | ERCC1 3834/4885ERCC4 3774/4885ARG1 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.